Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.31), $0.02 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $254.6 million versus the consensus estimate of $254.93 million.

GUIDANCE:

Tandem Diabetes sees FY2026 revenue of $1.06-1.08 billion, versus the consensus of $1.08 billion.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.